development of BRB breakdown and increased water diffusion in the retina under 8 diabetes conditions. A single intravitreous injection of TRPV4 antagonist is 9 however not sufficient to revert these alterations in diabetic mouse retinas.
homeostatic processes that needs to be deciphered in normal and diabetic retina.
8
Based on previous findings showing that TRPV4 antagonists resolve blood-retina 9 barrier (BRB) breakdown in diabetic rats, we evaluated whether TRPV4 channel 10 inhibition prevents and reverts retinal edema in streptozotocin(STZ)-induced 11 diabetic mice. We assessed retinal edema using common metrics, including retinal 12 morphology/thickness (histology) and BRB integrity (albumin-associated tracer), 13 and also by quantifying water mobility through apparent diffusion coefficient (ADC) 14 measures. ADC was measured by diffusion-weighted magnetic resonance imaging 15 (DW-MRI), acquired ex vivo at 4 weeks after STZ injection in diabetes and control 16 groups. DWI images were also used to assess retinal thickness. TRPV4 was 17 genetically ablated or pharmacologically inhibited as follows: left eyes were used 18 as vehicle control and right eyes were intravitreally injected with TRPV4-selective 19 antagonist GSK2193874, 24 h before the end of the 4 weeks of diabetes.
20 Histological data show that retinal thickness was similar in nondiabetic and diabetic 21 wt groups but increased in diabetic Trpv4 -/mice. In contrast, DWI shows retinal 22 thinning in diabetic wt mice that was absent in diabetic Trpv4 -/mice. Disorganized 23 outer nuclear layer was observed in diabetic wt but not in diabetic Trpv4 -/retinas. 24 We further demonstrate increased water diffusion and BRB hyperpermeability in 1 diabetic wt mice, effects that were absent in diabetic Trpv4 -/mice. Retinas of 2 diabetic mice treated with PBS showed increased water diffusion that was not 3 inhibited by GSK2193874. ADC maps in nondiabetic Trpv4 -/mouse retinas 4 showed restricted diffusion. Our data provide evidence that water diffusion is 5 increased in diabetic mouse retinas and that TRPV4 function contributes to retinal 6 hydro-ionic homeostasis and structure under control conditions, and to the 4
Non-diffusion weighted images were used to check retinal structure after 5 intravitreal injections. Of note, anatomical MRI revealed that some Trpv4 -/eyes (2 6 out of 11) showed an enlarged lens capsule (Supplemental Fig. 3 ).
8
Histology.
9
Mouse eyes were fixed for 3 hours at room temperature in 4 % paraformaldehyde. 18 All results were replicated in three or more independent experiments. All data were 19 reported as mean ± s.e.m. All data showed normal distribution and equal variance 20 according to D'Agostino-Pearson omnibus and Levene's tests, respectively.
21 Comparisons between groups were determined by ANOVA (R Studio). Differences 22 between means with P < 0.05 were considered statistically significant. 12 TRPV4 contributes to retinal structure and is necessary for BRB rupture and 13 increased water diffusion in diabetic mouse retinas.
14 The histology of Trpv4 -/retinas appeared relatively similar to that of wild-type mice 15 except for the OLM that is blurry and the spaces between photoreceptor nuclei that 16 are reduced in Trpv4 -/retinas ( Fig. 1A) . Cell bodies can also be seen in both the 17 outer and inner plexiform layers of Trpv4 -/retinas ( Fig. 1A) . Compared with 18 nondiabetic wt retinas, diabetic wt retinas showed a disorganized outer nuclear 19 layer with photoreceptor cell bodies that lost their round shape and alignment and 20 were separated by large irregular spaces. Additionally, the OLM was not visible, 21 cell bodies could be detected in the outer plexiform layer, and the ganglion cell 22 bodies became oval in diabetic wt retinas (Fig. 1A) . The histology of diabetic Trpv4 -23 /retinas appeared similar to that of nondiabetic Trpv4 -/retinas; spaces between 24 photoreceptor nuclei looked bigger and the inner nuclear layer thicker ( Fig. 1A) .
1 Compared to diabetic wt retinas, diabetic Trpv4 -/retinas displayed an organized 2 outer nuclear layer and thicker inner retina ( Fig. 1A ). Total and inner retina 3 thickness was increased in diabetic Trpv4 -/retinas ( Fig. 1B) . We found no 4 significant changes in retinal pigment epithelium (not shown) and outer retinal layer 5 thickness (Fig. 1B) .
6
The retina was easily observable through DWI in all groups (Fig. 1C ) and appeared 7 thinner in the streptozotocin-treated wt animals (Fig. 1D ). Quantification of DWI-8 retinal thickness showed that diabetic wt mice had thinner retinas compared to 9 nondiabetic wt mice (Fig. 1E ). This effect was absent in diabetic Trpv4 -/mice ( Fig.   10 1E) . Retinal thickness in nondiabetic Trpv4 -/mice was indistinguishable from that 11 of nondiabetic wt mice (Fig. 1E) . These effects were not focal but observed 12 throughout the retina (not shown).
13 Quantification of ADC maps ( Fig. 2A) showed an increase (+ 25 ± 2 %) in retinal 14 mean ADC values in diabetic wt mice (Fig. 2B) , an effect that was absent in 15 diabetic Trpv4 -/mice (Fig. 2B) . Nondiabetic Trpv4 -/retinas displayed a 20 ± 1 % 16 decrease in mean ADC values compared with the nondiabetic wt group (Fig. 2B ).
17 To support these observations, we measured BRB breakdown using the Evans 18 blue technique, given that in the streptozotocin mouse preclinical model of 23 stained albumin tripled (Fig. 2C) . The streptozotocin-induced BRB breakdown was 1 not observed in Trpv4 -/mice (Fig. 2C ). Lack of Trpv4 did not modify the basal 2 transport through the BRB (Fig. 2C ).
3
Effect of single intravitreal injection of TRPV4 antagonist GSK2193874 in diabetic
4 mouse retina.
5
Slight retinal/vitreous interface disruption at the intravitreal injection site was 6 observed on the non-diffusion weighted images, but general structure was overall 7 well conserved (Fig. 3A) . DWI data (Fig. 3B ) demonstrated that injection of either 8 vehicle or GSK2193874 did not affect total retinal thickness ( Fig. 1D vs. 3C).
9
Diabetic wt mice showed thinning of the retina if vehicle was administered ( Fig.   10 3C) . This overall effect was not prevented by TRPV4 antagonist administration 11 (Fig. 3C ). Retinal thinning occurred throughout the entire retina of diabetic mice 12 and GSK2193874 rescued retinas from streptozotocin-induced thinning 0 to 50º 13 from the optic nerve (nasal part of the retina) ( Fig. 3D ). Using ADC maps (Fig. 4A) , 14 we found a streptozotocin-induced increase in mean ADC values (Fig. 4B ) that was 15 still present in the eyes of diabetic mice treated with GSK2193874 ( Fig. 4B ).
16 GSK2193874 did not modify mean ADC values in nondiabetic mice (Fig. 4B ).
17 Similar to Figure 3D , Figure 4C shows that mean ADC values increased 18 throughout the entire retina of diabetic mice and that GSK2193874 did not block 19 this increase. 21 Our results likely identify vasogenic edema in diabetic mouse retinas because they 22 show increased water diffusion and loss of BRB integrity. Nevertheless, we cannot 23 specifically attribute the large irregular spaces between photoreceptor nuclei to 24 increased extracellular space or intracellular cell swelling.
1
The reason for subnormal ADC values in Trpv4 -/retinas is somewhat unclear.
2 Intracellular swelling may cause reduced water mobility. In this sense, TRPV4
3 mediates regulatory volume decrease -i.e., decrease in swelling in the presence of 8
Previous findings showed that TRPV4 blockade preserves the lung (Thorneloe et   9 al., 2012) and brain from vasogenic edema . We found that a 23 1996), our findings may contribute to treatment development for DME arising from 24 both type 1 and type 2 diabetes. This is of importance considering that more than 1 90 % of diagnosed patients suffer from a type-2 diabetes phenotype. Further 2 studies using in vivo DWI and OCT are also warranted to help determine 3 responses to potential treatment.
5
We conclude that TRPV4 contributes to the cascade of events that involve the 6 breaking of BRB, which is the stage prior to DME onset. Further experiments are 7 needed to test whether selective inhibition of TRPV4 by GSK2193874 has curative 8 potential for patients with DME. The role of TRPV4 may also extend to other types 9 of retinal edema. 
